Browse the evidence

Whey protein supplementation and exercise did not impact back pain reports.

Practitioners should be aware that these interventions may not alleviate back pain.

The cohort of 618 participants was successfully recruited despite challenges, exceeding the target of 600.

Successful recruitment strategies can be applied to similar trials.

Interim results on industry-led food reformulation did not meet the countries’ targets.

Practitioners should be aware that current reformulation efforts may not be effective in achieving public health targets.

Information asymmetries exist between food industry and policy makers.

Policy makers should seek independent data to inform nutrition policies.

The data provided by food industry actors represent a distorted snippet of the marketing intelligence system.

Practitioners should critically evaluate data from food industry sources before implementing policies.

Four nights of sleep restriction did not alter resting energy metabolism in postmenopausal women.

Practitioners can note that while insulin sensitivity and fat oxidation are affected, resting metabolism remains stable with sleep restriction.

There was no statistically significant difference in total Medicare spending between the intervention and control groups (difference, -$133; P = .89).

Practitioners should note that intensive lifestyle interventions may not lead to reduced total Medicare spending.

Allowing Medicare coverage of anti-obesity medications could increase annual Part D costs by $3.1 billion or $6.1 billion depending on the percentage of newly eligible patients prescribed the drugs.

Practitioners should be aware of the potential financial implications of Medicare coverage for anti-obesity medications.

The marginal costs of Medicare coverage for anti-obesity drugs could decrease by up to 62.5% if products are approved for additional indications.

Practitioners should consider the potential for reduced costs if additional indications for anti-obesity drugs are approved.

The policy change of covering anti-obesity medications is likely to increase Medicare costs by low to middle tens of billions of dollars over ten years.

Practitioners should prepare for the potential long-term financial impact of Medicare's coverage of anti-obesity medications.

Obesity prevalence is projected to grow by 40% in the next decade.

Health professionals should prepare for increased obesity-related health issues.

There were no significant changes in peak VO2 or other cardiovascular measures with HU6 treatment.

HU6 may not improve cardiovascular function despite weight loss.

25,215 adverse event reports related to tirzepatide were identified, predominantly in the 65 to 85 age group.

Healthcare providers should be aware of the high volume of AE reports in older adults using tirzepatide.

Novel adverse event signals include thyroid mass, medullary thyroid carcinoma, and conditions affecting the reproductive system and breast.

Clinicians should be vigilant for these specific adverse events in patients treated with tirzepatide.

The direct to consumer genetic testing market is estimated to total about $100 million in 2017.

Practitioners should be aware of the significant financial scale of the DTC genetic testing market.

There is limited clinical trial data on the safety and efficacy of anti-obesity medications for patients with heart failure.

Practitioners should be aware of the limited evidence when considering anti-obesity medications for heart failure patients.

The prevalence of obesity has increased markedly in recent decades, constituting major medical and socioeconomic problems worldwide.

Awareness of the obesity epidemic is crucial for public health initiatives.

There are currently no clear guidelines for the prehabilitation of obese patients with dysglycemia undergoing bariatric surgery.

Healthcare providers should recognize the need for developing guidelines for prehabilitation in this patient population.

Measured daily average CO2 production rates were not significantly different between the diets.

Dietary composition may not significantly affect metabolic rates as measured by CO2 production.

Challenges in ensuring safety, tolerability, and equitable access are critical barriers to advancing anti-obesity pharmacotherapy.

Address these barriers to improve obesity treatment outcomes.

Obesity is projected to affect 3.8 billion people worldwide by 2050.

Practitioners should be aware of the increasing obesity trend and its implications for health.

The global prevalence of obesity has risen sharply during the past half-century, reaching pandemic proportions.

Clinicians should be aware of the increasing obesity rates as a public health concern.

Conventional drug therapies explored in OSA have generally produced disappointing results.

Practitioners should be aware that current drug therapies for OSA may not be effective.

Cardiovascular-Renal-Hepatic-Metabolic diseases are increasing globally, posing significant challenges for patient care and clinical research.

Healthcare providers should be aware of the increasing prevalence of these diseases.